NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®)1 now recommend that physicians consider AR-V7 testing to help guide treatment selection post abiraterone or enzalutamide therapy in mCRPC patients.

Changes to NCCN Guidelines® regarding AR-V7 testing have been made in PROS-17 (Systemic Therapy for M1 CRPC: Adenocarcinoma without Visceral Metastases) and PROS-18 (Systemic Therapy for M1 CRPC: Adenocarcinoma with Visceral Metastases).*

  • Change in NCCN Guidelines regarding AR-V7 testing highlights significant advances in understanding the role of AR-V7 as a biomarker of resistance to androgen receptor (AR)-targeted therapies like abiraterone and enzalutamide
  • The recommendation to consider AR-V7 testing to help guide selection of therapy is Category 2A for mCRPC patients
  • Oncotype DX AR-V7 Nucleus Detect test is the only assay proven to detect resistance to AR-targeted therapies with near-absolute specificity2,3

Oncotype DX AR-V7 Nucleus Detect assay is the first and only liquid biopsy test that detects the AR-V7 protein variant in circulating tumor cells

Confidently select your next treatment option for mCRPC patients who have already received and failed an AR-targeted therapy






REFERENCES
*Pages 26 and 27 of NCCN Guidelines 2.2019
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2019. ©National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed [April17, 2019]. To view the most recent and complete version of the guideline, go online to NCCN.org.
  2. Scher et al. JAMA Oncol. 2016.
  3. Scher et al. JAMA Oncol. 2018

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™